Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Excessive Pricing of Pharmaceuticals in the EU: Balancing between Exploitation and Exploitative Abuse

Excessive Pricing of Pharmaceuticals in the EU: Balancing between Exploitation and Exploitative... AbstractNormally, after the end of the exclusivity period offered by patents, medicines fall in public domain attracting competing companies to launch generic production that would bring down price levels. for different reasons, generic production of off-patented medicines does not always take place, allowing the main producer to continue dictate price levels. under some circumstances, this conduct may turn into exploitative abuse. However, excessive pricing itself is not anti-competitive unless other cost-and non-cost-related factors are present that turn excessive pricing a concern of competition law.The article analyses the most relevant Eu case-law on abusive pricing in the pharmaceutical sector questioning what the right benchmark price is in the light of the United Brands two-limb test. As economic calculations cannot provide universal solutions in these cases, the article suggests that the United Brands test should not be the only method to judge exploitative abuse, but rather a combination of different methods that need to be applied to achieve reliable results. As emphasised in several cases, both economic calculations and other factors should be considered to avoid the risk of false-positive results. furthermore, exploitative abuse exists only in case excessive pricing is additionally unfair. However, judging unfairness, as discussed in this article, is a complicated task where the outcomes depend on the impact of the test results on the competition process. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Baltic Journal of European Studies de Gruyter

Excessive Pricing of Pharmaceuticals in the EU: Balancing between Exploitation and Exploitative Abuse

Minn, Mari
Baltic Journal of European Studies , Volume 10 (3): 18 – Dec 1, 2020
Download PDF
18 pages

Loading next page...
 
/lp/de-gruyter/excessive-pricing-of-pharmaceuticals-in-the-eu-balancing-between-DvGSQ0dI4t
Publisher
de Gruyter
Copyright
© 2020 Mari Minn, published by Sciendo
ISSN
2228-0596
eISSN
2674-4619
DOI
10.1515/bjes-2020-0023
Publisher site
See Article on Publisher Site

Abstract

AbstractNormally, after the end of the exclusivity period offered by patents, medicines fall in public domain attracting competing companies to launch generic production that would bring down price levels. for different reasons, generic production of off-patented medicines does not always take place, allowing the main producer to continue dictate price levels. under some circumstances, this conduct may turn into exploitative abuse. However, excessive pricing itself is not anti-competitive unless other cost-and non-cost-related factors are present that turn excessive pricing a concern of competition law.The article analyses the most relevant Eu case-law on abusive pricing in the pharmaceutical sector questioning what the right benchmark price is in the light of the United Brands two-limb test. As economic calculations cannot provide universal solutions in these cases, the article suggests that the United Brands test should not be the only method to judge exploitative abuse, but rather a combination of different methods that need to be applied to achieve reliable results. As emphasised in several cases, both economic calculations and other factors should be considered to avoid the risk of false-positive results. furthermore, exploitative abuse exists only in case excessive pricing is additionally unfair. However, judging unfairness, as discussed in this article, is a complicated task where the outcomes depend on the impact of the test results on the competition process.

Journal

Baltic Journal of European Studies – de Gruyter

Published: Dec 1, 2020

Keywords: balancing competition law; EU; exploitative abuse; pharmaceuticals; patents

There are no references for this article.